

Special Issue

Advances in Antiepileptic Drugs

Message from the Guest Editor

Today, pharmacotherapy is a major aspect of the therapeutic management of patients with most conditions. In almost every disease entity, pharmaceuticals can be used either as monotherapy or as polytherapy, depending on the need. The situation is similar for antiepileptic drugs (AEDs). AEDs have been known since 1938, when phenytoin was introduced. Today, there are three generations of AEDs, of which the third generation is defined as those introduced after 2000. AEDs have diverse mechanisms of action, the most commonly cited being potentiation of GABA, blockade of voltage-dependent sodium or calcium channels, or inhibition of glutamate-induced excitation. In addition to the treatment of epilepsy (including severe epileptic syndromes such as Dravet syndrome or Lennox Gastaut), AEDs are also used in the treatment of psychiatric disorders (e.g., bipolar disorder), neurological disorders (e.g., neuropathic pain, migraine), as well as in some neurosurgical patients. Despite enormous progress in medical and pharmaceutical science, there is still a need to find safer and more effective therapies.

Guest Editor

Dr. Barbara Miziak

Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/126199

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).